Alimentary Health Launches Pharmabiotic Subsidiary, AHPD,

Alimentary Health, global leader in Probiotic Technology, formally launches pharmabiotc subsidary, Alimentary Health Pharma Davos (AHPD)

Davos, Switzerland March 21st 2014

Alimentary Health, has today formally launched its new pharmabiotic subsidiary, Alimentary Health Pharma Davos (AHPD) at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland.

In conjunction with the launch, AHPD scientists at WIRM will be presenting mechanistic data from new studies which consider a novel approach to the management of systemic inflammation. This work will be progressed through a combination of grant funding and pharma industry collaboration.

Building on the science of a patented and well documented probiotic culture Bifidobacterium infantis 35624 (B. infantis 35624), the research provides a possible roadmap to identify anti-inflammatory effects beyond the gut in patients with inflammatory conditions such as psoriasis.  Greater understanding of this mechanism may provide new pathways for drug development and other therapeutic options.

Commenting on the launch of AHPD, Alimentary Health co-founder and CEO, Dr. Barry Kiely said:

“Alimentary Health has over a decade of experience working on anti-inflammatory bacteria from the human microbiome, and the launch of AHPD represents a logical extension of our expertise in this area. This is ground-breaking work, which, if successful, could result in an entirely new platform for the management of inflammatory diseases and the potential for exciting new drugs and therapies”

Dr Liam O’Mahony, Chief Scientific Officer at AHPD added

“This is exciting science andWe are delighted to be able to conduct this important work here in Switzerland, collaborating with the Swiss Institute of Allergy and Asthma Research (SIAF), to pave the way for a deeper understanding of the link between gastrointestinal health and inflammatory conditions.”

Alimentary Health, founded in 1999, is a spin-out company from University College Cork (UCC) and a founding member of the Alimentary Pharmabiotic Centre (APC).  The APC at UCC has received global recognition as one of the world’s leading institutions in probiotic research. 1

Alimentary Health has already seen significant commercial success in other markets, as a result of strategic alliances with leading global healthcare players. Alimentary Health licensed the probiotic strain B. infantis 35624 to Procter & Gamble (P&G) in 2005 who today market B.infantis 35624 under the brand name Align® in the United States and Canada.  Align® is now the number one Gastroenterologist-recommended probiotic product in the US.2

Alimentary Health has a strong technology pipeline of new probiotic cultures in addition to B. infantis 35264.  It has also developed a portfolio containing over 100 patents across multiple territories.

More information on the Swiss Institute of Allergy and Asthma Research (SIAF) can be found at


1Thomson Reuters Science Watch, Ranking of Global Institutions Number of Citations on Special Topics

2Among Gastroenterologists who recommended a brand of probiotic in a Walters Kluwer 2011 survey.